BB Biotech has announced a profit of CHF 76 million for 2024, marking its first positive outcome in four years. This recovery comes after consecutive losses totaling CHF 207 million in the previous year.

Despite the profit, the company’s share price closed at CHF 35.40, reflecting an annual decline of 13.5 percent. The declines were even more pronounced in other currencies, with decreases of 14.1 percent in euros and 18.1 percent in dollars. Additionally, the net asset value (NAV) experienced a 3 percent increase in Swiss francs, but fell by 4.6 percent in US dollars, resulting in a discount on NAV of 15.2 percent as of December 31.

Shareholders will receive a reduced dividend of CHF 1.80 per share, down from CHF 2.00 last year, which yields 5 percent. Key upcoming dates include the Annual General Meeting set for March 19, 2025, and the publication of the full annual report on February 21. BB Biotech is managed by Bellevue Asset Management, located in Zurich.

📎 Read the original article on finews.ch